In the phase 3 KEYNOTE-181 trial, pembrolizumab as second-line therapy for advanced oesophageal cancer (OAC/OSCC) did not improve OS in the whole population, compared to chemotherapy, but did improve survival for patients with strong expression of PDL1 (CPS ≥10) (156). Here, CD274 is linked to carcinoma of esophagus.